Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
55 GBX | +5,77% | +4,76% | -11,29% |
Omzet 2024 * | 15,35 mln. 19,17 mln. 17,93 mln. | Omzet 2025 * | 103 mln. 129 mln. 121 mln. | Marktkapitalisatie | 1,01 mld. 1,26 mld. 1,17 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -83 mln. -104 mln. -96,94 mln. | Nettowinst (verlies) 2025 * | -38 mln. -47,47 mln. -44,38 mln. | EV/omzet 2024 * | 53,6 x |
Nettoliquiditeiten 2024 * | 184 mln. 230 mln. 215 mln. | Nettoliquiditeiten 2025 * | 146 mln. 183 mln. 171 mln. | EV/omzet 2025 * | 8,32 x |
K/w-verhouding 2024 * |
-24,1
x | K/w-verhouding 2025 * |
-81,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 75,42% |
Recentste transcriptie over Verona Pharma plc
1 dag | +5,77% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 59 | 01-02-20 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 01-03-20 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 17-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 12-09-16 |
David Ebsworth
CHM | Chairman | 69 | 01-12-14 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers VRNA
- Koers VRP